Patient-Reported Outcomes in Patients with Chronic Migraine Receiving Placebo or Erenumab (AMG 334) in a Phase 2, Randomized, Double-Blind Study

被引：0

作者：

Tepper, Stewart ^{[1
]}

Lipton, Richard ^{[2
]}

Reuter, Uwe ^{[3
]}

Silberstein, Stephen ^{[4
]}

Stewart, Walter ^{[5
]}

Leonardi, Dean ^{[6
]}

Desai, Pooja ^{[7
]}

Cheng, Sunfa ^{[8
]}

Mikol, Dan ^{[8
]}

Lenz, Robert ^{[8
]}

机构：

[1] Geisel Sch Med Dartmouth, Hanover, NH USA

[2] Albert Einstein Coll Med, Dept Neurol, Bronx, NY USA

[3] Charlie Univ Med Berlin, Dept Neurol, Berlin, Germany

[4] Thomas Jefferson Univ, Jefferson Headache Ctr, Philadelphia, PA USA

[5] Sutter Hlth, Walnut Creek, CA USA

[6] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA USA

[7] Amgen Inc, Global Hlth Econ, Thousand Oaks, CA USA

[8] Amgen Inc, Global Dev, Thousand Oaks, CA USA

来源：

NEUROLOGY | 2017年 / 88卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P2.167

引用

页数：3

共 50 条

[31] Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: A double-blind, randomized, placebo-controlled study
Fagien, Steven
Cox, Sue Ellen
Finn, J. Charles
Werschler, W. Philip
Kowalski, Jonathan W.
DERMATOLOGIC SURGERY, 2007, 33 : S2 - S9
[32] Erenumab impact on patient-reported outcomes in chronic migraine in the presence of acute medication overuse
Tepper, Stewart J.
Ashina, Messoud
Klatt, Jan
Desai, Pooja
Zhang, Feng
Cheng, Sunfa
Mikol, Daniel D.
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[33] Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Tepper, Stewart
Ashina, Messoud
Reuter, Uwe
Brandes, Jan L.
Dolezil, David
Silberstein, Stephen
Winner, Paul
Leonardi, Dean
Mikol, Daniel
Lenz, Robert
LANCET NEUROLOGY, 2017, 16 (06): : 425 - 434
[34] Erenumab Impact on Patient-reported Outcomes in Chronic Migraine in Presence of Acute Medication Overuse
Tepper, S. J.
Ashina, M.
Klatt, J.
Desai, P.
Zhang, F.
Cheng, S.
Mikol, D.
HEADACHE, 2018, 58 : 160 - 162
[35] Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients
Robinson, Dudley
Kelleher, Con
Staskin, David
Mueller, Elizabeth R.
Falconer, Christian
Wang, Jianye
Ridder, Arwin
Stoelzel, Matthias
Paireddy, Asha
van Maanen, Rob
Hakimi, Zalmai
Herschorn, Sender
NEUROUROLOGY AND URODYNAMICS, 2018, 37 (01) : 394 - 406
[36] Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
Takeshima, Takao
Sakai, Fumihiko
Hirata, Koichi
Imai, Noboru
Matsumori, Yasuhiko
Yoshida, Ryuji
Peng, Cheng
Cheng, Sunfa
Mikol, Daniel D.
HEADACHE, 2021, 61 (06): : 927 - 935
[37] A Randomized, Double-Blind, Placebo-Controlled Study of Erenumab Safety in Patients with Stable Angina
Depre, C.
Antalik, L.
Starling, A. J.
Koren, M.
Eisele, O.
Mikol, D.
HEADACHE, 2018, 58 : 177 - 177
[38] Phase 1, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Erenumab (AMG 334) and Concomitant Sumatriptan on Blood Pressure in Healthy Subjects
de Noon, Jan
Van Hecken, Anne
Vandermeulen, Corinne
Herbots, Marissa
Kubo, Yumi
Lee, Ed
Eisele, Osa
Vargas, Gabriel
Gabriel, Kristin
NEUROLOGY, 2017, 88
[39] Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study
Detke, Holland C.
Goadsby, Peter J.
Wang, Shufang
Friedman, Deborah I.
Selzler, Katherine J.
Aurora, Sheena K.
NEUROLOGY, 2018, 91 (24) : E2211 - E2221
[40] Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers
de Hoon, Jan
van Hecken, Anne
Vandermeulen, Corinne
Herbots, Marissa
Kubo, Yumi
Lee, Ed
Eisele, Osa
Vargas, Gabriel
Gabriel, Kristin
CEPHALALGIA, 2019, 39 (01) : 100 - 110

← 1 2 3 4 5 →